Related references
Note: Only part of the references are listed.Drug-Induced Progressive Multifocal Leukoencephalopathy: Lessons Learned From Contrasting Natalizumab and Rituximab
N. S. Vermeer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
Carol Moreno et al.
HAEMATOLOGICA (2015)
Progressive Multifocal Leukoencephalopathy Associated with Belimumab in a Patient with Systemic Lupus Erythematosus
Charlotte Leblanc-Trudeau et al.
JOURNAL OF RHEUMATOLOGY (2015)
Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis
Dominic Borie et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
Carol Moreno et al.
HAEMATOLOGICA (2015)
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives
Dejan Pavlovic et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Tatiana Plavina et al.
ANNALS OF NEUROLOGY (2014)
Reply to Magnetic Resonance Imaging-Based Diagnosis of Progressive Multifocal Leukoencephalopathy in a Patient With Non-Hodgkin Lymphoma After Therapy With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab
Charles L. Bennett et al.
CANCER (2014)
Progressive Multifocal Leukoencephalopathy Associated With Brentuximab Vedotin Therapy A Report of 5 Cases from the Southern Network on Adverse Reactions (SONAR) Project
Kenneth R. Carson et al.
CANCER (2014)
Treating Progressive Multifocal Leukoencephalopathy With Interleukin 7 and Vaccination With JC Virus Capsid Protein VP1
Mireia Sospedra et al.
CLINICAL INFECTIOUS DISEASES (2014)
Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era
J. L. Casado et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy
Federico Serana et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab
C. A. Fredericks et al.
LUPUS (2014)
Treatment of Progressive Multifocal Leukoencephalopathy With Interleukin 7
Karl B. Alstadhaug et al.
JAMA NEUROLOGY (2014)
Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs
Vishvas Garg et al.
EXPERT OPINION ON DRUG SAFETY (2013)
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing
Monica E. Mazda et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2013)
PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section
Joseph R. Berger et al.
NEUROLOGY (2013)
An agenda for UK clinical pharmacology Pharmacovigilance
I. Ralph Edwards
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Brentuximab associated progressive multifocal leukoencephalopathy
Pankaj Jalan et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2012)
Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin
Nina D. Wagner-Johnston et al.
LEUKEMIA & LYMPHOMA (2012)
Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases
A. Bharat et al.
ARTHRITIS CARE & RESEARCH (2012)
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps
Fariha Zaheer et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2012)
Immune reconstitution inflammatory syndrome in natalizumab-associated PML
I. L. Tan et al.
NEUROLOGY (2011)
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents
Carlo Piccinni et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
David B. Clifford et al.
LANCET NEUROLOGY (2010)
Incidence of progressive multifocal leukoencephalopathy in patients without HIV
K. L. Amend et al.
NEUROLOGY (2010)
Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy
Marco Tuccori et al.
ONCOLOGIST (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (vol 9, pg 438, 2010)
D. B. Clifford et al.
LANCET NEUROLOGY (2010)
Progressive Multifocal Leukoencephalopathy A National Estimate of Frequency in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Eamonn S. Molloy et al.
ARTHRITIS AND RHEUMATISM (2009)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Progressive Multifocal Leukoencephalopathy Following Heightened Immunosuppression After Lung Transplant
Jesse Waggoner et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2009)
PML-IRIS in patients with HIV infection Clinical manifestations and treatment with steroids
K. Tan et al.
NEUROLOGY (2009)
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
Werner Wenning et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Quantitative signal detection using spontaneous ADR reporting
A. Bate et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Immune reconstitution associated with progressive multifocal leukoencephalopathy in human immunodeficiency virus - A case discussion and review of the literature
Jennifer Travis et al.
NEUROLOGIST (2008)
Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders:: Impact of novel therapies
J García-Suárez et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
The Rresearch on Adverse Drug Events and Reports (RADAR) project
CL Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Under-reporting of serious adverse drug reactions in Sweden
M Bäckström et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2004)
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
SJW Evans et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2001)
Spontaneous adverse event signaling methods: Classification and use with health care treatment products
JA Clark et al.
EPIDEMIOLOGIC REVIEWS (2001)